DUBLIN--(BUSINESS WIRE)--The "Human Microbiome: The Unavoidable Companion Technological Report and Market Scenario" report has been added to ResearchAndMarkets.com's offering.
The global human microbiome market is nearly expected to grow by $521.23 million in 2022
This report provides an in-depth diverse perspective and the importance of human microbiome in health and disease-related conditions. Alterations in human microbiome occur by exposure to various extrinsic factors like diet, xenobiotics, drugs as well as pathogens which contribute to the pathogenesis of various metabolic, neurological, immunological, and cancer-promoting diseases. It will also disclose the key aspects of the human microbiome as well as the current biotechnological tools and techniques for studying the human microbiome.
Various human microbial studies are known to identify and categorize the bacterial taxa and functions that are shared by a majority of individuals. This report will cover the factors which can affect the human microbiome as well as various studies which are well known and can be used as a tool for identifying the potential of the functional microbiome. It will also emphasize on the various microbiome-based markers which can be useful in determining the disease or the risk of disease and various approaches like Fecal Microbiota Transplant (FMT), Genetically engineered probiotics, etc. which have a profound effect in improving the microbiome condition.
This report covers its market trends analysis and its growth in the commercial market. It will also include the major key players like Agilent technologies, Abbott, Biocartis, etc. which are actively working in this field and will also be discussed its future market scenario.
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 Introduction
4 Human Microbiome: Overview
5 Research Scope
6 Research Methodology
7 Research Approach
8 Research Sources
9 Technical Analysis
10 Mode of Administration of Microbiome Products
11 Microbiome Product forms
12 Market Analysis
13 Market Trend Analysis
14 Key Microbiome Players (Company Profiling)
- 4D Pharma plc
- Abbott Diagnostics
- Agilent Technologies Inc.
- Anaeropharma Science
- AOBiome, LLC
- Aperiomics, Inc.
- Atlas Biomed
- AvidBiotics
- Beckman Coulter/Danaher
- Becton, Dickinson and Company (BD)
- Biocartis Group
- C3J Therapeutics (formerly C3 Jian)
- Crestovo (Finch Therapeutics Group)
- Danaher Corporation
- Eppendorf AG
- Evelo Biosciences
- Evolve Biosystems
- Finch Therapeutics Group
- One Codex
- OpenBiome
- Optibiotix
- OraSure Technologies, Inc.
- Osel, Inc.
- PerkinElmer, Inc. (Pe)
- Pfizer, Inc.
- Phase Genomics
- Proderm IQ
- Prodigest
- Promega Corporation
- PureFlora Inc.
- QIAGEN
- Quay Pharma
- Whole Biome
- Xycrobe Therapeutics, Inc.
- Zymo Research
For more information about this report visit https://www.researchandmarkets.com/research/4qb2jm/human_microbiome?w=4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
